1. What is the clinically relevant endpoint for cancer prevention trials?

   • Maurie Markman

   Editor’s Commentary Pages: 329 - 330

2. Web alert

   News Pages: 331 - 332

3. Literature alert

   Abstract Pages: 333 - 335

4. Novel approaches to immunotherapy for B-cell malignancies

   • Renier J. Brentjens

   OriginalPaper Pages: 339 - 347

5. Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia

   • Clive S. Zent
   • Neil E. Kay

   OriginalPaper Pages: 348 - 354

6. Clinical Trials Report

   • Carol S. Portlock

   BriefCommunication Pages: 357 - 359

7. New molecular targets for treatment of lymphoma

   • Barbara Pro
   • Anas Younes

   OriginalPaper Pages: 360 - 368

8. Molecular diagnosis in lymphoma

   • Adam Bagg

   OriginalPaper Pages: 369 - 379

9. The genetics of familial lymphomas

   • Rina Siddiqui
   • Kenan Onel
   • Kenneth Offit

   OriginalPaper Pages: 380 - 387

10. Primary central nervous system lymphoma

    • Igor T. Gavrilovic
    • Lauren E. Abrey

    OriginalPaper Pages: 388 - 395

11. Clinical Trials Report

    • Kim Margolin

    BriefCommunication Pages: 399 - 400

12. Melanoma genomics

    • Mohammed Kashani-Sabet

    OriginalPaper Pages: 401 - 405

13. Chemoprevention of melanoma

    • Marie-France Demierre
    • Glenn Merlino

    OriginalPaper Pages: 406 - 413

14. Overview of melanoma vaccines and promising approaches

    • Monica C. Panelli
    • Ena Wang
    • Francesco M. Marincola

    OriginalPaper Pages: 414 - 420